title: Therapeutic effects of hMAPC and hMSC transplantation after stroke in mice.
abstract: Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 2(-/-) γC(-/-) mice subjected to FeCl(3) thrombosis mediated stroke were intracranially injected with 2 × 10(5) hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison with PBS-treated animals, hMSC and hMAPC grafted animals demonstrated significantly decreased loss of brain tissue. This was associated with increased angiogenesis, diminished inflammation and a glial-scar inhibitory effect. Moreover, enhanced proliferation of cells in the subventricular zone (SVZ) and survival of newly generated neuroblasts was observed. Interestingly, these neuroprotective effects were more pronounced in the group of animals treated with hMAPCs in comparison with hMSCs. Our results establish cell therapy with hMAPCs and hMSCs as a promising strategy for the treatment of stroke.
authors.affiliation: Hematology and Cell Therapy Area, Clinica Universidad de Navarra and Division of Cancer, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
authors.forename: Silvia
authors.initials: S
authors.lastname: Mora-Lee
authors.forename: Ma Salomé
authors.initials: MS
authors.lastname: Sirerol-Piquer
authors.forename: María
authors.initials: M
authors.lastname: Gutiérrez-Pérez
authors.forename: Ulises
authors.initials: U
authors.lastname: Gomez-Pinedo
authors.forename: Valerie D
authors.initials: VD
authors.lastname: Roobrouck
authors.forename: Tania
authors.initials: T
authors.lastname: López
authors.forename: Mayte
authors.initials: M
authors.lastname: Casado-Nieto
authors.forename: Gloria
authors.initials: G
authors.lastname: Abizanda
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Rabena
authors.forename: Catherine
authors.initials: C
authors.lastname: Verfaille
authors.forename: Felipe
authors.initials: F
authors.lastname: Prósper
authors.forename: Jose Manuel
authors.initials: JM
authors.lastname: García-Verdugo
mesh_terms: D053687:Adult Stem Cells / Q000166:cytology / Q000637:transplantation*; D000818:Animals; D001921:Brain / Q000098:blood supply / Q000473:pathology; D002465:Cell Movement; D002470:Cell Survival; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000473:pathology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D051379:Mice; D039902:Multipotent Stem Cells / Q000166:cytology / Q000637:transplantation*; D018919:Neovascularization, Physiologic; D020521:Stroke / Q000473:pathology / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*